viewTilray Inc

Short-seller Andrew Left’s Citron Research says surge in cannabis company Tilray is 'beyond comprehension'

Left was previously bullish on Tilray but has since changed his tune

Marijuana plant
Left has called out cannabis companies Cronos and Namaste Technologies as well

Tilray Inc (NASDAQ:TLRY) set the cannabis space ablaze following an interview with CNBC’s Jim Cramer, sending its shares surging double digits. But short-seller Andrew Left’s Citron Research had some harsh words to share about the Canadian cannabis company.

Citron Research was previously bullish on Tilray following Constellation Brands Inc‘s (NYSE:STZ) additional US$4bn investment in its rival Canopy Growth Inc (NYSE:CGC, TSX:WEED).

READ: Tilray CEO encourages pharmaceutical and alcohol companies to enter the cannabis space

Left had said it could be the next marijuana company to get a “white knight at a premium to market.”

The short-seller has cast doubt on other cannabis stocks via Twitter Inc (NYSE:TWTR) as well, including Cronos Group Inc (NASDAQ:CRON, CSE:CRON) and Namaste Technologies Inc (CVE:N, OTCQB:NXTTF).

Shares of Tilray soared nearly 50% to US$232 in Wednesday pre-market trading.

Quick facts: Tilray Inc

Price: 7.38 USD

Market: NASDAQ
Market Cap: $921.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



SōRSE Technology sees 'soaring' cannabis sales in western states, positive...

SōRSE Technology CEO Howard Lee tells Proactive the privately-held water-soluble CBD, hemp, and terpene emulsion provider has positive outlook on future of cannabis industry Lee says while cannabis legalization in states like New York and New Jersey has stalled during the coronavirus pandemic,...

2 days, 17 hours ago

2 min read